MRNA

Moderna
D

MRNA

246.890
USD
-3.92
(-1.56%)
Pre Open·252.480USD+5.590(+2.26%)
Last updated: · Delayed 15 min
Q4 FY2026 · Earnings report
EPS estimate -2.01Revenue estimate 556.40M
OverviewFinancialsSignalsForecastEarningsCompany

Moderna cash on hand 2016–2026

Moderna had 1.20B USD in cash and short-term investments on 30 September 2026, down 73.5% on a year before. At the end of fiscal year 2025 it had 5.80B USD.

Last updated 6 Nov 2026 · Next report 12 Feb 2027

Cash on hand

Growth

Fiscal yearPeriod endingCash on handGrowthTotal debtNet cash
Latest quarter30 Sept 20261.20B-73.47%4.18B-2.98B
FY202531 Dec 20255.80B-17.45%1.90B3.90B
FY202431 Dec 20247.03B-18.35%747.00M6.28B
FY202331 Dec 20238.60B-13.11%1.24B7.36B
FY202231 Dec 20229.90B-7.69%1.20B8.70B
FY202131 Dec 202110.73B+132.79%916.00M9.81B
FY202031 Dec 20204.61B+317.77%237.00M4.37B
FY201931 Dec 20191.10B-27.50%132.36M970.64M
FY201831 Dec 20181.52B+101.24%33.49M1.49B
FY201731 Dec 2017756.03M-28.55%15.69M740.34M
FY201631 Dec 20161.06B—12.50M1.05B

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Total debt,Free cash flow,Stock buybacks,Balance sheet

Common questions about Moderna's cash

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.